Skye Bioscience Inc.近日公布其研发战略，计划在2026年中期正式启动一项针对肥胖症治疗的2B期临床试验。该试验将重点评估其核心候选药物Nimacimab与奥洛兹美医疗（Halozyme Therapeutics）专有的Enhanze药物递送技术联合应用的疗效与安全性。
这一临床进展标志着Skye在代谢疾病治疗领域迈出了关键一步。Nimacimab作为一种创新疗法，结合Enhanze技术旨在增强药物递送效率，有望为肥胖患者提供新的治疗选择。公司预计该试验将为后续临床开发提供重要数据支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.